

Telomere Therapeutics appoints Dr. Michael Tadros Chief Executive Officer

Michael is a seasoned professional in the realm of technology transfer and venture capital, skillfully connecting scientific research with commercial innovation.

Michael is transitioning to CEO, after proving successful leadership in gene therapy product development.

Madrid, Barcelona, April 17th, 2024. Telomere Therapeutics, a preclinical-stage biotechnology company developing a new **telomerase gene therapy** to treat **age-related diseases**, today announced the appointment of **Michael Tadros, Ph.D.**, as the company's **new Chief Executive Officer**.

Michael, who brings extensive **C-level experience** in biotech gene therapy from his roles as **Chief Operating Officer** and **interim Chief Executive Officer** at Telomere Therapeutics, is now assuming the position of CEO at the organization. His career highlights include serving as **global Chief Operating Officer** and **Chief Executive Officer EU** of **Danaus Pharmaceuticals**, where he demonstrated his ability in bringing gene editing therapy to patients in record time since inception. Prior to that, he spent over 14 years as **Senior Manager** of the **Science Department of the Botín Foundation**, an auspice of the Banco de Santander and the largest philanthropic foundation in Spain. Before joining the Botín Foundation, Michael was **Manager of CrossRoadBiotech Venture Capital**, a venture capital management firm that invests in the development of seed stage companies in life sciences. Additionally, he held the position of **Head of Technology Transfer and Innovation** at the **National Cancer Research Center (CNIO)** of the Ministry of Health. He received his Ph.D. from the **National Center for Biotechnology of the University of Madrid** with Honor Cum Laude in Molecular Microbial Biology.

“Since onset, Telomere Therapeutic´s course is set to patient-centric; our drive and sole motivation is to urgently provide patients suffering of a truly devastating disease with a much-needed therapeutic treatment. On behalf of Telomere Therapeutics, we are honored to continue on this worthy journey, surrounded by a truly talented and fully engaged team, founding scientists, and our dedicated investors.”, said Michael Tadros, CEO.

Michael is transitioning to the role of CEO after three years of effectively serving as COO and interim CEO. Under his leadership, the scientific team has developed a distinctive regenerative approach capable of **halting** and **reversing** the **progression** of **idiopathic pulmonary fibrosis (IPF)** in **animal models**. IPF marks the initial indication within the telomere syndromes that the company can address. This innovative therapy seeks to provide IPF patients with a curative, effective and safe

treatment that facilitates the restoration of lung function and regression of pulmonary fibrosis. Moreover, the company has raised **over €5.8 million from Invivo Ventures, CDTI-Innvierte and competitive non-dilutive funding.**

"We are delighted to welcome Dr. Michael Tadros as the new CEO of Telomere Therapeutics. Michael has consistently demonstrated his ability to connect pioneering scientific research with practical innovations in the biotech sector. His guidance is especially valuable at this pivotal time for Telomere Therapeutics as we strive to turn the potential of telomerase gene therapy into tangible benefits for those affected by age-related diseases," said Laura Rodríguez, a board member at Telomere Therapeutics.

About Telomere Therapeutics

Telomere Therapeutics S.L., a **spin-off** of the **National Cancer Research Centre** (CNIO) and the **Autonomous University of Barcelona** (UAB), was established in November 2020, by founding scientists **Dr. María Blasco** and **Dr. Fàtima Bosch**, following years of collaborative research and numerous joint scientific publications by the internationally renowned researchers.